Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Neovacs is running a Phase IIb trial on its lead immunotherapy project, IFN-Kinoid (IFN-K) for lupus. The US arm is now recruiting and is expanding from five to 15 centres due to strong interest. We now expect results from end 2017, formerly mid-2017. In Korea, CKD may start sales in 2018, but the main impact is likely to be in 2019. Partnering for other territories is now expected from mid-2018. The important VEGF-Kinoid for cancer and AMD might start Phase I in H117. Cash at the end of June 2016 was &#8364;9.2m.</p>

Neovacs is running a Phase IIb trial on its lead immunotherapy project, IFN-Kinoid (IFN-K) for lupus. The US arm is now recruiting and is expanding from five to 15 centres due to strong interest. We now expect results from end 2017, formerly mid-2017. In Korea, CKD may start sales in 2018, but the main impact is likely to be in 2019. Partnering for other territories is now expected from mid-2018. The important VEGF-Kinoid for cancer and AMD might start Phase I in H117. Cash at the end of June 2016 was &#8364;9.2m.

France

Neovacs is a biotechnology company.  The Company researches immunotherapy applications for autoimmune diseases, inflammatory diseases such as rheumatoid arthritis, cancer and other conditions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Neovacs (ALNEV FP)

US trial generates strong interest

Neovacs is running a Phase IIb trial on its lead immunotherapy project, IFN-Kinoid (IFN-K) for lupus. The US arm is now recruiting and is expanding...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)